NASDAQ
558.88USD
+18.88 (+3.50%)
We have scored 76 news catalysts on Vertex Pharmaceuticals Incorporated (VRTX) over the past 12 months. The biggest single-day move next to one of them came Dec 3, 2025, when VRTX closed +6.9%: “S&P500: US Indices Gain on Rate-Cut Hopes Despite Tech Stocks Pressure Today”. Coverage across the window leans positive (average ticker sentiment +0.43). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
141.7B
P/E
—
EPS
—
Beta
0.32
52W range
403.16-563.8
Day range
549.89–563.80
Open
551.15
Prev close
540.00
Volume
2.9M
Avg volume
1.4M
Dividend
0.00
IPO
1991-07-24
Analysts publish price targets on VRTX, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
14 analyst price targets from $350 to $665
as of 2026-09-04
The market is within 2% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Vertex Pharmaceuticals Incorporated — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Vertex Pharmaceuticals Incorporated, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for VRTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
The price sits at the 29th percentile of the 14 published models, just 2% below the median, meaning it broadly agrees with the middle of the street but explicitly rejects the most bullish growth scenarios and the most bearish decline assumptions.
What the disagreement turns on
Whether the Crinetics assets and the broader pipeline can accelerate revenue growth fast enough to meet the 15.8% annual rate the price already requires, which cannot be settled by the wired data because unit volumes for unreleased drugs are not yet measurable.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $558 on 2026-09-04 — 57 days ago.
